Replies to post #190008 on Biotech Values

[DewDiligence]

Re: Other generic Copaxone products

…after going through the CP, the approval process just seems a lot more difficult/complicated than enox. This seems to be quite bullish for MNTA.

Well, the Copaxone approval certainly took longer than Lovenox (88 months vs 60 months). Moreover, Craig Wheeler said that MNTA has learned from its IP mistakes on Lovenox, implying that MNTA’s IP on Copaxone manufacturing—see #msg-59682546—may be able to keep other generics off the market.